Due to these identified and potential differences, several organizations, including the United States Food and Drug Administration , the European Medicines Agency , and the World Health Organization , regard LMWHs as individual products that should not be considered as clinically equivalent, as they differ in many crucial aspects such as molecular, structural, physiochemical, and biological properties.    According to international guidelines, the choice of an individual LMWH should be based on its proven clinical safety and efficacy for each indication. 
For severe relapses (involving loss of vision, severe weakness or poor balance, for example), which interfere with a person’s mobility, safety or overall ability to function, most neurologists recommend treatment with corticosteroids. The most common treatment regimen is a three-to-five-day course of high-dose, intravenous corticosteroids to reduce inflammation and end the relapse more quickly. This regimen may or may not be followed with a slow taper of oral prednisone. Corticosteroids are not believed to have any long-term benefit on the disease. Medication options include:
A combination of nonsteroidal anti-inflammatory drugs and muscle relaxants -- such as cyclobenzaprine (Flexeril), diazepam (Valium), carisoprodol (Soma), or methocarbamol (Robaxin) -- are sometimes used for patients with acute low back pain. Evidence has shown that they can help relieve non-specific low back pain, but some experts warn that these drugs should be used cautiously, since they target the brain, not the muscles. Patients who take muscle relaxants may experience a number of central nervous system side effects, such as drowsiness. The muscle relaxant Soma can be addictive and does little more than induce sleep.